Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo C...
BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and raises the price target from $6 to $9.
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech &...
Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that i...
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of...
Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$18...
